Inventor
Xiaodong Wang
Inventor
Chapel Hill, NC, US
Overview
Patents· 87 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Dprimary
C07DHeterocyclic compounds25%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations24%
A61KPreparations for medical, dental or toiletry purposes19%
C07KPeptides8%
C07CAcyclic or carbocyclic compounds6%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium4%
C07BGeneral methods of organic chemistry4%
C12NMicroorganisms or enzymes2%
G01NInvestigating or analysing materials by determining their chemical or physical properties2%
Y02ATechnologies for adaptation to climate change2%
PatentTitleYear
10,836,759Thiazole derivatives useful as mutant IDH1 inhibitors for treating cancer202010,736,883Triazole furan compounds as agonists of the APJ receptor202010,703,746Mutant IDH1 inhibitors useful for treating cancer202010,682,319Necrosis inhibitors202010,676,456Polycyclic amines as opioid receptor modulators202010,555,920Necrosis inhibitors202010,526,309Pan-TAM inhibitors and Mer/Axl dual inhibitors202010,221,162Triazole agonists of the APJ receptor201910,179,133Pyrrolopyrimidine compounds for the treatment of cancer201910,150,760Compounds for use in preparing heterocyclic triazole agonists of the APJ receptor201810,092,529Necrosis inhibitors201810,058,550Methods of treating heart failure201810,004,755Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity20189,988,369Heterocyclic triazole compounds as agonists of the APJ receptor20189,974,762Necrosis inhibitors20189,868,721'Triazole agonists of the APJ receptor'20189,845,310Intermediates for preparing triazole agonists of the APJ receptor20179,795,606'Pyrrolopyrimidine compounds for the treatment of cancer'20179,771,330'Pyrimidine compounds for the treatment of cancer'20179,751,864'Methods for preparing triazole agonists of the APJ receptor'20179,744,172'Pyrazolopyrimidine compounds for the treatment of cancer'20179,745,286'Triazole agonists of the APJ receptor'20179,687,433'Anhydrous depigmenting compositions comprising phenolic compounds'20179,656,998'Intermediates for preparing triazole agonists of the APJ receptor'20179,656,997'Triazole agonists of the APJ receptor'20179,649,309'Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity'20179,603,850'MerTK-specific pyrazolopyrimidine compounds'20179,593,129'Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer'20179,573,936'Triazole agonists of the APJ receptor'20179,567,326'Pyrimidine compounds for the treatment of cancer'20179,562,047'Pyrazolopyrimidine compounds for the treatment of cancer'20179,555,030'Therapeutic uses of selected pyrazolopyrimidine compounds with anti-Mer tyrosine kinase activity'20179,555,031'Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity'2017RE046129'Dimeric small molecule potentiators of apoptosis'20169,376,425'Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer'20169,296,736'Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer'20169,290,499'Pyrazolopyrimidine compounds for the treatment of cancer'20169,273,056'Pyrrolopyrimidine compounds for the treatment of cancer'20168,980,903'Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors'20158,841,312'Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors'20148,389,533'Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors'20138,338,608'Inhibitors of ion channels'20128,143,418'Dimeric small molecule potentiators of apoptosis'20128,124,610'Sodium channel inhibitors'20128,063,080'Inhibitors of ion channels'20117,884,211'Dimeric small molecule potentiators of apoptosis'20117,816,538'Dimeric small molecule potentiators of apoptosis'20107,786,108'Compounds and method for treating dyslipidemia'20107,777,051'Asymmetric benzimidazoles and related compounds as potassium channel modulators'20107,749,992'Compounds and methods for treating dislipidemia'20107,732,446'Dipeptidyl peptidase inhibitors'20107,709,533'Imines as ion channel modulators'20107,705,158'Inhibitors of ion channels'20107,701,372'Apparatus and methods for safe-mode delta-sigma modulators'20107,678,792'Compositions and methods for modulating c-kit and PDGFR receptors'20107,655,641'Sulfonamide derivatives as PPAR modulators'20107,642,354'Polycyclic pyrazines as potassium ion channel modulators'20107,638,544'Dimeric small molecule potentiators of apoptosis'20097,622,106'Necrosis assay'20097,622,289'Ornithine aminotransferase (OAT): a target for anticancer drugs'20097,615,569'Inhibitors of ion channels'20097,560,464'Polycyclic pyrimidines as potassium ion channel modulators'20097,544,812'Peroxisome proliferator activated receptor agonists'20097,528,160'Fused heterocyclic derivatives as PPAR modulators'20097,504,433'Thiophene derivative PPAR modulators'20097,482,373'Bis-benzimidazoles and related compounds as potassium channel modulators'20097,470,705'Compounds and methods for treating dyslipidemia'20087,459,457'Polycyclic pyridines as potassium ion channel modulators'20087,309,792'Dimeric small molecule potentiators of apoptosis'20077,304,062'Peroxisome proliferator activated receptor alpha agonists'20077,303,887'Mule: Mcl-1 ubiquitination ligase E3'20077,144,714'R2D2: an enzyme of RNA silencing'20067,132,439'Bis-benzimidazoles and related compounds as potassium channel modulators'20067,094,758'Apoptotic compounds'20067,041,784'Apoptotic compounds'20066,790,648'DNA fragmentation factor involved in apoptosis'20046,608,026'Apoptotic compounds'20036,558,900'Regulation of apoptosis and in vitro model for studies thereof'20036,534,267'Polynucleotides encoding activators of caspases'20036,515,118'DNA fragmentation factor'20036,346,607'APAF-1 an activator of caspase-3'20026,291,643'Apaf-1 an activator of caspase-3'20016,165,737'DNA fragmentation factor involved in apoptosis'20006,110,691'Activators of caspases'20005,891,631'Methods relating tosterol regulatory element binding proteins'19995,527,690'Methods and compositions relating to sterol regulatory element binding proteins'19965,498,696'Sterol regulatory element binding proteins and their use in screening assays'1996Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1996–2016Patents assigned to UNIV TEXAS (21)· patent assignee history
1996–2012Based in Dallas, TX, US· patent location history
2006–2012Patents assigned to ICAGEN INC (12)· patent assignee history
2006–2020Based in Chapel Hill, NC, US· patent location history
2007–2010Patents assigned to LILLY CO ELI (8)· patent assignee history
2007–2010Based in Carmel, IN, US· patent location history
2013–2020Patents assigned to AMGEN INC (18)· patent assignee history
2016–2020Based in Beijing, CN· patent location history
2017–2020Patents assigned to UNIV NORTH CAROLINA CHAPEL HILL (14)· patent assignee history
2017–2020Based in Johns Creek, GA, US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| UNIV TEXAS | 21 | 1996–2016 |
| AMGEN INC | 18 | 2013–2020 |
| UNIV NORTH CAROLINA CHAPEL HILL | 14 | 2017–2020 |
| ICAGEN INC | 12 | 2006–2012 |
| LILLY CO ELI | 8 | 2007–2010 |
Locations
| Location | Patents | Span |
|---|---|---|
| Chapel Hill, NC, US | 30 | 2006–2020 |
| Dallas, Texas, US | 23 | 1996–2012 |
| Johns Creek, Georgia, US | 13 | 2017–2020 |
| Carmel, IN, US | 8 | 2007–2010 |
| Beijing, CN | 5 | 2016–2020 |